Market Intelligence, Clinical Progress, and High-Purity Reagents for Spliceosomal and Rare Genetic Disorder Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SNRPN drug discovery, optimized for antisense oligonucleotide (ASO) screening, spliceosome assembly studies, and Prader-Willi Syndrome (PWS) model construction.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SNRPN Recombinant Protein (Full-Length, Wild-Type & Mutant variants available) High purity (>95%), Sequence Verified. E. coli or HEK293 expressed. Endotoxin <1 EU/µg. Full-length and domain truncations available. |
View SNRPN Products |
| Gene Delivery | SNRPN Lentivirus Particles & Promise-ORF Full-length ORF for stable cell line construction and splicing reporter co-expression. CMV promoter, Puromycin selection. |
View SNRPN Products |
| Detection / Benchmark Ab | Anti-SNRPN Monoclonal Antibody Recombinant, Sequence Verified. Validated for Western Blot, IP, ICC/IF (nuclear staining). |
View SNRPN Products |
| Validator | SNRPN siRNA Set (3 unique sequences) Sequence-verified for knockdown verification and on-target specificity control. |
View SNRPN Products |
| Related Target 1 | UBE3A Co-located in 15q11-q13 imprinted region (Angelman syndrome). Functional antagonist in imprinting balance. |
View UBE3A Products |
| Related Target 2 | SMN1 Direct interactor in SMN complex; chaperone for snRNP biogenesis and alternative splicing. |
View SMN1 Products |
| Related Target 3 | SNURF Bicistronic partner protein co-expressed with SNRPN from same mRNA; important for PWS region studies. |
View SNURF Products |
| Related Target 4 | MAGEL2 Adjacent PWS-region gene functionally linked to SNRPN in neurodevelopment. |
View MAGEL2 Products |
| Related Target 5 | SNRPE Core Sm protein heterodimer partner; essential for snRNP assembly and protein-protein interaction assays. |
View SNRPE Products |
| Related Target 6 | SNRPD2 Central Sm domain protein; critical paralog for spliceosome selectivity counter-screening. |
View SNRPD2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Sm Core Ring Assembly & PPI Mapping (RNA-protein and protein-protein binding) | Purified SNRPN (>95%) with endotoxin <1 EU/µg; compatible with SPR, BLI, AlphaScreen, and Co-IP workflows. |
| Nuclear Localization Verification & snRNP Incorporation | Anti-SNRPN Ab validated for nuclear staining (ICC/IF); full-length protein for BLI/SPR with U1/U2 snRNA. |
| Paralog Selectivity (SNRPB/SNRPE/SNRPD2) | Ortholog and paralog panels strictly sequence-verified by mass spectrometry to ensure off-target screening accuracy. |
| Cross-species Translation (PWS/AS Models) | Human / Mouse / Cyno SNRPN proteins available with theoretical MW confirmation for preclinical assay bridging. |
| Loss-of-Function Validation | Sequence-verified siRNA set included for knockdown; lentivirus ORF enables rescue experiments. |
| Allele-Specific ASO Screening | Matched SNRPN and SNURF protein pairs for off-target assessment; high-specificity antibodies for allele-specific quantification. |
Live SNRPN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (General)
- ➤ PWS-Specific Clinical Trials
- ➤ Latest ASO Research & Resistance Mechanisms
- ➤ Latest Mechanism Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The therapeutic landscape for SNRPN is defined by two converging R&D fronts: rare genetic disorder biology centered on the 15q11-q13 imprinted region, and fundamental spliceosome research in oncology. For Prader-Willi Syndrome (PWS), the focus is shifting from supportive care to disease-modifying therapies such as antisense oligonucleotides (ASOs) aimed at reactivating the silenced maternal allele, with first-in-class ASO candidates entering clinical evaluation. In parallel, the role of SNRPN in spliceosome assembly has attracted attention in oncology, where spliceosome-addicted solid tumors and hematologic malignancies are being targeted through small-molecule modulators and emerging modalities like molecular glues and PROTACs. Accurate cellular modeling and high-purity protein reagents are mandatory for accelerating these next-generation modalities, including selectivity assays against paralog Sm proteins to avoid global splicing toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players / Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ASO / RNAi | Ionis Pharmaceuticals, Biogen, Rare Disease Biotechs | Prader-Willi Syndrome, SMA | Allele-specific protein quantification; need high-specificity SNRPN antibodies and lentivirus for reporter cell lines. |
| Epigenetic Editing | Academic Consortia, Startups | Prader-Willi Syndrome | Allele reactivation validation; need high-purity recombinant controls and lentivirus for stable models. |
| Gene Therapy (AAV) | Academic Consortia, Rare Disease Biotechs | PWS, Autism Spectrum Disorders | Functional protein expression validation; need full-length SNRPN lentivirus and antibodies. |
| Small Molecule (Spliceosome Modulators) | Oncology-focused Pharma, Pharma Research Divisions | Solid Tumors, Hematologic Malignancies | Binding & selectivity assays vs. paralog Sm proteins; need purified SNRPN, SNRPE, SNRPD2 antigens. |
| Molecular Glue / PROTAC (Emerging) | Preclinical academic-industry consortia | Spliceosomopathies | Ternary complex formation; need full-length SNRPN with native folding and partner proteins. |